Related Experiment Video
Updated: Jul 8, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Eosinophilic Endomyocarditis After COVID-19 Infection in a Heart Transplant Recipient
Sara S Inglis1, Anshul R Gupta2, Francisco B Alexandrino1
1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Abstract:
Eosinophilic myocarditis (EM) is a rare cause of heart failure, with high in-hospital mortality associated with fulminant disease. A 61-year-old female transplant recipient was diagnosed with COVID-19 after presenting with 2 days of constitutional symptoms. She developed acute heart failure from EM. After an initial response to inotropic support and corticosteroids, she had a relapse with de novo peripheral eosinophilia which responded to further eosinophilic myocarditis management and the addition of mepolizumab. Although there have been reports after COVID-19 vaccination, association with active SARS-CoV-2 infection is rare. This paper reports, for the first time, the case of a heart transplant recipient with EM after COVID-19.
Related Concept Videos
Endocarditis I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis III: Medical Management
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management

